

Amoxicillin + clavulanic acid

Statut de médicament essentiel

Description générale

Amoxicillin is an extended spectrum penicillin antibiotic. Clavulanic acid is a beta-lactamase inhibitor.

INN

Amoxicillin + clavulanic acid

Codes ATC

[J01CR02](#)

Type de médicament

Chemical agent

Groupes d'antibiotiques

[ACCESS](#)

Historique des statuts LME

Ajouté pour la première fois en 1997 ([TRS 882](#)) pour [Bacterial infection of unspecified site](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Acute otitis media](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Infectious cystitis](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Chronic obstructive pulmonary disease with acute exacerbation](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Acute sinusitis](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Bacterial cellulitis, erysipelas or lymphangitis](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Osteomyelitis or osteitis](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Bacterial infection of joint](#)

Retiré en 2017 ([TRS 1006](#)) pour [Bacterial infection of unspecified site](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Neutropenia](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Peritoneal abscess](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Peritonitis](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Bacterial pneumonia](#)

Ajouté en 2017 ([TRS 1006](#)) pour [Other specified pneumonia](#)

Ajouté en 2019 ([TRS 1021](#)) pour [Other specified prophylactic measures](#)

Ajouté en 2019 ([TRS 1021](#)) pour [Multi-drug resistant Mycobacterium tuberculosis](#)

Wikipédia

[Amoxicillin + clavulanic acid](#)

DrugBank

[Amoxicillin](#),

[Clavulanic acid \(Clavulanate\)](#)

Recommandations

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

**Premier choix**

[Chronic obstructive pulmonary disease with acute exacerbation](#) [Infectious cystitis](#) [Acute sinusitis](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Neutropenia \(low-risk\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritonitis \(mild-moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

**Second choix**

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Acute otitis media](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Other specified prophylactic measures](#)

Autres indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)